ZA200303915B - Oral extended release formulation of gepirone. - Google Patents
Oral extended release formulation of gepirone. Download PDFInfo
- Publication number
- ZA200303915B ZA200303915B ZA200303915A ZA200303915A ZA200303915B ZA 200303915 B ZA200303915 B ZA 200303915B ZA 200303915 A ZA200303915 A ZA 200303915A ZA 200303915 A ZA200303915 A ZA 200303915A ZA 200303915 B ZA200303915 B ZA 200303915B
- Authority
- ZA
- South Africa
- Prior art keywords
- gepirone
- amount
- extended release
- tablets
- pharmaceutical
- Prior art date
Links
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 title claims description 27
- 229960000647 gepirone Drugs 0.000 title claims description 27
- 239000000203 mixture Substances 0.000 title claims description 26
- 238000013265 extended release Methods 0.000 title claims description 12
- 238000009472 formulation Methods 0.000 title claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 238000000034 method Methods 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000009491 slugging Methods 0.000 description 3
- 241000237858 Gastropoda Species 0.000 description 2
- 238000012369 In process control Methods 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- -1 glidants Substances 0.000 description 2
- 238000010965 in-process control Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000001034 iron oxide pigment Substances 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012735 once-a-day formulation Substances 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00204388 | 2000-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200303915B true ZA200303915B (en) | 2004-08-20 |
Family
ID=8172397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200303915A ZA200303915B (en) | 2000-12-08 | 2003-05-20 | Oral extended release formulation of gepirone. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1343504A2 (cs) |
| JP (1) | JP2004517083A (cs) |
| KR (1) | KR20040018314A (cs) |
| CN (1) | CN1479620A (cs) |
| AR (1) | AR031461A1 (cs) |
| AU (1) | AU2002226371A1 (cs) |
| BR (1) | BR0115976A (cs) |
| CA (1) | CA2436692A1 (cs) |
| CZ (1) | CZ20031589A3 (cs) |
| EC (1) | ECSP034627A (cs) |
| HU (1) | HUP0401021A2 (cs) |
| IL (1) | IL155855A0 (cs) |
| MX (1) | MXPA03005099A (cs) |
| NO (1) | NO20032581L (cs) |
| PL (1) | PL362445A1 (cs) |
| RU (1) | RU2003120446A (cs) |
| SK (1) | SK6942003A3 (cs) |
| WO (1) | WO2002045753A2 (cs) |
| ZA (1) | ZA200303915B (cs) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004028507A1 (en) * | 2002-09-24 | 2004-04-08 | Akzo Nobel N.V. | Method to improve pharmaceutical tablets having a matrix of cellulose ether |
| AU2004324868B2 (en) * | 2004-11-05 | 2010-04-29 | Fabre Kramer Holdings Inc | High-dosage extended-release formulation of gepirone |
| MY198454A (en) * | 2017-07-26 | 2023-08-29 | Abbott Lab | Nutritional Tablets and Methods of Making the Same |
| CN109745323A (zh) * | 2017-11-01 | 2019-05-14 | 四川科瑞德制药股份有限公司 | 氮哌酮类化合物提高副交感神经活性的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
-
2001
- 2001-11-30 CZ CZ20031589A patent/CZ20031589A3/cs unknown
- 2001-11-30 PL PL01362445A patent/PL362445A1/xx not_active Application Discontinuation
- 2001-11-30 BR BR0115976-3A patent/BR0115976A/pt not_active Application Discontinuation
- 2001-11-30 RU RU2003120446/15A patent/RU2003120446A/ru not_active Application Discontinuation
- 2001-11-30 CN CNA018201792A patent/CN1479620A/zh active Pending
- 2001-11-30 SK SK694-2003A patent/SK6942003A3/sk unknown
- 2001-11-30 AU AU2002226371A patent/AU2002226371A1/en not_active Abandoned
- 2001-11-30 KR KR10-2003-7007555A patent/KR20040018314A/ko not_active Withdrawn
- 2001-11-30 MX MXPA03005099A patent/MXPA03005099A/es unknown
- 2001-11-30 CA CA002436692A patent/CA2436692A1/en not_active Abandoned
- 2001-11-30 HU HU0401021A patent/HUP0401021A2/hu unknown
- 2001-11-30 EP EP01995688A patent/EP1343504A2/en not_active Withdrawn
- 2001-11-30 JP JP2002547535A patent/JP2004517083A/ja not_active Withdrawn
- 2001-11-30 IL IL15585501A patent/IL155855A0/xx unknown
- 2001-11-30 WO PCT/EP2001/014189 patent/WO2002045753A2/en not_active Application Discontinuation
- 2001-12-07 AR ARP010105683A patent/AR031461A1/es not_active Application Discontinuation
-
2003
- 2003-05-20 ZA ZA200303915A patent/ZA200303915B/en unknown
- 2003-05-28 EC EC2003004627A patent/ECSP034627A/es unknown
- 2003-06-06 NO NO20032581A patent/NO20032581L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0401021A2 (hu) | 2004-09-28 |
| NO20032581D0 (no) | 2003-06-06 |
| KR20040018314A (ko) | 2004-03-03 |
| MXPA03005099A (es) | 2004-02-12 |
| EP1343504A2 (en) | 2003-09-17 |
| AU2002226371A1 (en) | 2002-06-18 |
| NO20032581L (no) | 2003-06-06 |
| SK6942003A3 (en) | 2003-10-07 |
| BR0115976A (pt) | 2003-12-30 |
| IL155855A0 (en) | 2003-12-23 |
| CA2436692A1 (en) | 2002-06-13 |
| WO2002045753A2 (en) | 2002-06-13 |
| JP2004517083A (ja) | 2004-06-10 |
| ECSP034627A (es) | 2004-09-28 |
| AR031461A1 (es) | 2003-09-24 |
| CZ20031589A3 (cs) | 2003-11-12 |
| PL362445A1 (en) | 2004-11-02 |
| WO2002045753A3 (en) | 2002-08-29 |
| CN1479620A (zh) | 2004-03-03 |
| RU2003120446A (ru) | 2005-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0914119B1 (en) | Process for forming solid oral dosage forms of valsartan | |
| JP2638389B2 (ja) | 経口投与後のインダパミドの徐放性マトリックス錠剤 | |
| EP1351668B1 (en) | Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles | |
| US6103263A (en) | Delayed pulse release hydrogel matrix tablet | |
| US20110071137A1 (en) | Process for preparing sustained release tablets | |
| US20110177168A1 (en) | Composition | |
| EP0744942A1 (en) | Controlled release hydrogel formulation | |
| KR100465895B1 (ko) | 파라세타몰을 포함하는 경구용 정제 | |
| AU5748299A (en) | Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative | |
| HUP0301390A2 (hu) | Valzartánt tartalmazó orális gyógyászati készítmény | |
| WO2006103551A1 (en) | Controlled release formulations of oxycodone | |
| JPH1036268A (ja) | 経口経路による投与後のチアネプチンナトリウム塩の持続性放出を可能とするマトリックス錠 | |
| ZA200303915B (en) | Oral extended release formulation of gepirone. | |
| CA2493593A1 (en) | Bicifadine formulation | |
| US20240415777A1 (en) | Instant release pharmaceutical preparation of anticoagulant and preparation method therefor | |
| US20030152621A1 (en) | Pharmaceutical formulation of gepirone for oral administration | |
| HUT75461A (en) | Laxative compositions | |
| EP0950419B1 (en) | A solid preparation and a method of manufacturing it | |
| EP1560568B1 (en) | Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate | |
| WO2005092293A1 (en) | Formulations of metformin | |
| CN119868292A (zh) | 一种阿普斯特缓冲剂片剂组合物及其制备方法 | |
| WO2007047040A2 (en) | Directly compressible extended release alprazolam formulation | |
| KR20050010843A (ko) | 활성 성분을 지속 방출시키는, 옥스카바제핀 함유약제학적 조성물 | |
| HK1019858B (en) | Process for forming solid oral dosage forms of valsartan |